Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022
2022年11月8日 - 9:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced it will
report its financial results from the third quarter ended September
30, 2022, before the financial markets open on Monday,
November 14, 2022.
The Company’s management team will host a conference call
at 8:00 a.m. ET on Monday, November 14, 2022. To
access the call, please dial 1-877-407-0789 in
the U.S. or 1-201-689-8562 outside the U.S. and
ask for the Viridian call. To access the live webcast, please visit
the “Events” page in the Investors section of the Viridian
Therapeutics website. Following the live webcast, the archived call
will be available on the website.
Monday, November 14 @ 8:00 a.m.
ET |
|
Domestic: |
1-877-407-0789 |
International: |
1-201-689-8562 |
Conference ID: |
13732927 |
Webcast: |
Webcast
Link |
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases
underserved by current therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and
incorporates half-life extension technology. VRDN-003 is an
extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003
are designed for administration as convenient, low-volume,
subcutaneous injections. TED is a debilitating autoimmune disease
that causes inflammation and fibrosis within the orbit of the eye
which can cause double vision, pain, and potential blindness.
Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:John JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024